Tallimustine in advanced previously untreated colorectal cancer, a phase II study

Authors:
  • YHY Humblet
    Y Humblet
  • ERE Roca
    E Roca
  • LDLy Dirix
    Ly Dirix
  • RWR Wainstein
    R Wainstein
  • APA Polli
    A Polli
  • ICI Corradino
    I Corradino

Abstract
Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previously untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 microgram m-2 once every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. Toxicity mainly consisted a highly selective neutropenia, which warrants further investigation of this agent in combination with myeloid growth factors.

This publication has 10 references indexed in Scilit: